	Application Number		10587054	
INFORMATION BIOOL COURT	Filing Date		2006-07-24	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Jame		es Pearson	
	Art Unit		1614	
	Examiner Name Unkn		ıknown	
	Attorney Docket Number	er	2221.008B	

U.S.PATENTS								Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	of cited Document			Lines where ges or Relev		
	1	3790580		1974-02	2-05	Johnson et al.					
If you wis	h to ac	dd additional U.S. Patei	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBI	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	of cited Document				Lines where ges or Relev	
	1	20030199529		2003-10	0-23	Garvey et al.					
If you wis	h to ac	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Add	d button	. Add		
				FOREIG	ON PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patentee Applicant of cited Document	or I	where Rel	or Relevant	T5
	1	03080607	WO			2003-10-02	Altana Pharma AG				
	2	0193867	WO			2001-12-13	Aventis Pharma S.	Α.			
	3	1297264	GB			1972-11-22	Fisons Pharmaceu	ticals			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10587054			
Filing Date		2006-07-24			
First Named Inventor Jame		s Pearson			
Art Unit		1614			
Examiner Name	Unkn	own			
Attorney Docket Number		2221.008B			

	4	2210398	FR		1974-07-12	Robert Aries				
	5	2196796	FR		1974-03-22	Robert Aries				
	6	2196795	FR		1974-03-22	Robert Aries				
	7	1374981	GB		1974-11-20	Fisons Ltd				
	8	398319	ES		1975-04-16	Instituto Luso-Farmaco				
	9	2326227	DE		1974-02-14	Fisons Ltd.				
If you wis	h to ac	dd additional Foreign P	atent Document	citation	information pl	ease click the Add buttor	Add			
			NON-PATEN	NT LITE	RATURE DO	CUMENTS	Remove			
Examiner Initials* Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T5			
	1									
If you wish to add additional non-patent literature document citation information please click the Add button Add										
EXAMINER SIGNATURE										
Examiner Signature Date Considered										
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10587054			
Filing Date		2006-07-24			
First Named Inventor Jame		s Pearson			
Art Unit		1614			
Examiner Name Unkn		own			
Attorney Docket Number		2221.008B			

¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10587054		
Filing Date		2006-07-24		
First Named Inventor	Jame	s Pearson		
Art Unit		1614		
Examiner Name	Unknown			
Attorney Docket Number		2221.008B		

	CERTIFICATION STATEMENT							
Plea	Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):							
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).							
OR	!							
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).							
	See attached cer	rtification statement.						
	Fee set forth in 3	7 CFR 1.17 (p) has been submitted herewit	h.					
✓	None							
		SIGNA	TURE					
	ignature of the ap n of the signature.	plicant or representative is required in accor	dance with CFR 1.33, 10.1	8. Please see CFR 1.4(d) for the				
Signature /Philip E. Hansen/ Date (YYYY-MM-DD) 2006-10-		2006-10-02						
Name/Print Philip E. Hansen		Philip E. Hansen	Registration Number	32700				
pub 1.14	lic which is to file (1. This collection i	mation is required by 37 CFR 1.97 and 1.98 (and by the USPTO to process) an application s estimated to take 1 hour to complete, inclue USPTO. Time will vary depending upon the	on. Confidentiality is gover uding gathering, preparing	rned by 35 U.S.C. 122 and 37 CFR and submitting the completed				

require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria**,

VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.